

Hamid Emamekhoo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6466427/hamid-emamekhoo-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37
papers

280
citations

9
h-index

15
g-index

45
ext. papers

491
ext. citations

4
avg, IF

2.77
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 37 | Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1529-1554 | 7.3 | 62 |
| 36 | HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018 , 128, 3333-3340 | 15.9 | 32 |
| 35 | Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 405-412 | 2.8 | 30 |
| 34 | Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4517-4517 | 2.2 | 23 |
| 33 | mutations predict shorter overall survival in urothelial cancer. <i>Oncotarget</i> , 2018 , 9, 16891-16898 | 3.3 | 13 |
| 32 | Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2018 , 13, 599-609 | 5 | 12 |
| 31 | Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2926-2937 | 2.2 | 10 |
| 30 | Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e751-e760 | 3.3 | 9 |
| 29 | Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. <i>Prostate</i> , 2018 , 78, 1035-1041 | 4.2 | 7 |
| 28 | Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer. <i>Oncologist</i> , 2020 , 25, 680-688 | 5.7 | 6 |
| 27 | Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 429-436 | 3.3 | 6 |
| 26 | Percutaneous microwave ablation for local control of metastatic renal cell carcinoma. <i>Abdominal Radiology</i> , 2018 , 43, 2446-2454 | 3 | 5 |
| 25 | Concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with locally advanced urothelial cancer of bladder (DUART): Btcr-GU15-023.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 513-513 | 2.2 | 5 |
| 24 | Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. <i>Frontiers in Oncology</i> , 2020 , 10, 581189 | 5.3 | 5 |
| 23 | Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 1536-1543 | 13.4 | 5 |
| 22 | PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS4596-TPS4596 | 2.2 | 4 |
| 21 | PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS5100-TPS5100 | 2.2 | 4 |

| | | | |
|----|---|-----|---|
| 20 | Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma. <i>Oncotarget</i> , 2016 , 7, 52442-52449 | 3.3 | 4 |
| 19 | Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma. <i>Molecular Oncology</i> , 2021 , 15, 2330-2344 | 7.9 | 4 |
| 18 | Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4515-4515 | 2.2 | 3 |
| 17 | Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. <i>Cancer</i> , 2021 , | 6.4 | 2 |
| 16 | Are liquid biopsies ready for primetime?. <i>Cancer</i> , 2019 , 125, 834-837 | 6.4 | 2 |
| 15 | Patterns and predictors of cancer-specific patient health portal usage among patients with cancer: results from the UWCCC Survivorship Program. <i>Cancer Medicine</i> , 2021 , 10, 7373-7382 | 4.8 | 2 |
| 14 | Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report. <i>Anticancer Research</i> , 2020 , 40, 1527-1534 | 2.3 | 1 |
| 13 | Outcomes with novel combinations in non-clear cell renal cell carcinoma(nccRCC): ORACLE study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4580-4580 | 2.2 | 1 |
| 12 | Image intensity histograms as imaging biomarkers: application to immune-related colitis. <i>Biomedical Physics and Engineering Express</i> , 2021 , 7, | 1.5 | 1 |
| 11 | Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 334-334 | 2.2 | 1 |
| 10 | Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. <i>Cancer</i> , 2021 , | 6.4 | 1 |
| 9 | PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS760-TPS760 | 2.2 | 0 |
| 8 | Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 1 | 8.8 | 0 |
| 7 | Phase II trial of neoadjuvant chemohormonal therapy (NAC) in prostate cancer (PC) with response assessment using PSMA PET/MRI.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 334-334 | 2.2 | |
| 6 | QIM21-080: Patterns of Patient Portal Use in Patients With Cancer Who Utilized the Portal Frequently: Results From the UWCCC Survivorship Program. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, QIM21-080 | 7.3 | |
| 5 | 18F-DCFPyL PSMA PET imaging compared to conventional imaging in the detection of pelvic nodal metastases in patients with locally advanced or oligometastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 36-36 | 2.2 | |
| 4 | Preoperative predictors of biochemical recurrence in a phase II trial of neoadjuvant therapy in very high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 74-74 | 2.2 | |
| 3 | A case of metastatic renal cell carcinoma with concomitant Castleman's disease treated with immunotherapy. <i>Urology Case Reports</i> , 2021 , 38, 101720 | 0.5 | |

- 2 Single cell phenotyping of PDL1 and HLA1 on circulating tumor cells (CTC) in clear cell renal cell carcinoma (ccRCC) on systemic treatment with immunotherapy (IO) and vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKI).. *Journal of Clinical Oncology*, **2022**, 40, 381-381 2.2
- 1 Impact of neoadjuvant immune checkpoint inhibitor therapy on primary tumor size and complexity: Correlation with surgical quality and short term oncological outcomes.. *Journal of Clinical Oncology*, **2022**, 40, 390-390 2.2